Compass Therapeutics Inc. (CMPX) News
Filter CMPX News Items
CMPX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CMPX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CMPX News From Around the Web
Below are the latest news stories about COMPASS THERAPEUTICS INC that investors may wish to consider to help them evaluate CMPX as an investment opportunity.
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateTop-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected.Two Phase 2 biomarker trials are expected to initiate in mid-2025: tovecimig (in DLL4-positive colorectal cancer) and CTX-471 (in NCAM/CD56 expressing tumors).Fully enrolled the thi |
US Penny Stocks To Watch In January 2025As the U.S. stock market navigates rising Treasury yields and strong economic data, investors are keenly watching how these factors might influence interest rates and broader market movements. Penny stocks, a term that may seem outdated but remains relevant, often represent smaller or less-established companies with potential value. By focusing on those with robust financials and clear growth prospects, investors can uncover opportunities in these under-the-radar stocks that might offer both... |
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerBOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. “We are de |
Top US Penny Stocks To Watch In December 2024As December 2024 unfolds, the U.S. stock market is experiencing a notable upswing, with the S&P 500 and Nasdaq reaching record highs amid a post-election rally. For investors seeking opportunities outside of large-cap stocks, penny stocks—despite their somewhat outdated moniker—remain an intriguing area for potential growth. These smaller or newer companies often offer unique opportunities at lower price points, especially when they are backed by solid financial fundamentals and robust... |
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024. Presentation detailsDate: Wednesday, December 4, 2024Time: 9:50-10:10 AM ESTWebcast Link: https://event.webcasts.c |
Compass Therapeutics to Participate in Upcoming Investor EventsBOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024. Details are as follows: Stifel 2024 Healthcare ConferenceLocation: New York, NYDate: Monday, November 18, 2024 Time: 3:00pm ETWebcast Link: https://wsw |
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate UpdateFully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first quarter of 2025.Designing a Phase 2 trial of CTX-009 in combination with chemotherapy in patients with DLL4-positive colorectal cancer (CRC) treated in the second-line setting; trial initiation expected in mid-2025.Identified neural cell adhesion molecule (NCAM or CD56) as a potential biomarker of r |
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNew data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study. BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- |
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40MAs the U.S. stock market experiences a rally led by the technology sector, investors are closely monitoring developments such as the presidential election and upcoming Federal Reserve decisions on interest rates. In this context, penny stocks continue to capture attention for their potential to offer both affordability and growth opportunities, despite being considered a somewhat outdated term. These smaller or newer companies can provide unique investment prospects when they demonstrate... |
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingBOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Post |